铜绿假单胞菌抗菌药物敏感性谱、耐药机制与国际克隆谱系:ESGARS-ESCMID/ISARPAE工作组更新
本文为ESGARS-ISARPAE工作组立场文件,由18个欧洲国家40余名研究者经四轮修订达成共识,更新铜绿假单胞菌对经典及新型抗假单胞菌药物的耐药机制、敏感谱、耐药定义影响及全球扩张的高风险谱系。
要点
- 铜绿假单胞菌通过染色体突变、可转移耐药决定簇及流行谱系全球扩张形成耐药。
- 文件聚焦产碳青霉烯酶和超广谱β-内酰胺酶等可转移耐药机制。
- 更新广耐药/难治性耐药国际高风险流行谱系与可转移耐药机制的关联。
核心结论
- 本文证据可用于欧洲及全球层面协调流行病学监测与决策。
研究设计与样本
- 欧洲临床微生物与感染病学会(ESCMID)下属欧洲抗菌药物耐药监测研究组(ESGARS)于2022年启动ISARPAE倡议,获抗微生物耐药联合规划网络征召支持。
- 专家组包括来自18个欧洲国家的40余名研究者,立场文件经四轮修订和全体成员讨论后达成最终版本。
主要发现
- 铜绿假单胞菌是医院获得性和慢性感染的主要病因之一,与显著发病率和死亡率相关。
- 其耐药性增长源于染色体突变、可转移耐药决定簇(如碳青霉烯酶和超广谱β-内酰胺酶)流行率增加及流行谱系全球扩张。
- 本文更新了对经典和新型抗假单胞菌药物(尤其β-内酰胺类)的新兴耐药机制、与主要β-内酰胺耐药机制相关的敏感谱、新型药物和耐药机制对耐药谱定义的影响,以及全球扩张的广耐药/难治性耐药高风险谱系与可转移耐药机制的关联。
临床怎么用
- 本文证据可用于欧洲和全球层面的协调流行病学监测与决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SCOPE: Pseudomonas aeruginosa, a ubiquitous opportunistic pathogen considered one of the paradigms of antimicrobial resistance, is among the main causes of hospital-acquired and chronic infections associated with significant morbidity and mortality. This growing threat results from the extraordinary capacity of P. aeruginosa to develop antimicrobial resistance through chromosomal mutations, the increasing prevalence of transferable resistance determinants (such as the carbapenemases and the extended-spectrum β-lactamases), and the global expansion of epidemic lineages. The general objective of this initiative is to provide a comprehensive update of P. aeruginosa resistance mechanisms, especially for the extensively drug-resistant (XDR)/difficult-to-treat resistance (DTR) international high-risk epidemic lineages, and how the recently approved β-lactams and β-lactam/β-lactamase inhibitor combinations may affect resistance mechanisms and the definition of susceptibility profiles. METHODS: To address this challenge, the European Study Group for Antimicrobial Resistance Surveillance (ESGARS) from the European Society of Clinical Microbiology and Infectious Diseases launched the 'Improving Surveillance of Antibiotic-Resistant Pseudomonas aeruginosa in Europe (ISARPAE)' initiative in 2022, supported by the Joint programming initiative on antimicrobial resistance network call and included a panel of over 40 researchers from 18 European Countries. Thus, a ESGARS-ISARPAE position paper was designed and the final version agreed after four rounds of revision and discussion by all panel members. QUESTIONS ADDRESSED IN THE POSITION PAPER: To provide an update on (a) the emerging resistance mechanisms to classical and novel anti-pseudomonal agents, with a particular focus on β-lactams, (b) the susceptibility profiles associated with the most relevant β-lactam resistance mechanisms, (c) the impact of the novel agents and resistance mechanisms on the definitions of resistance profiles, and (d) the globally expanding XDR/DTR high-risk lineages and their association with transferable resistance mechanisms. IMPLICATION: The evidence presented herein can be used for coordinated epidemiological surveillance and decision making at the European and global level.
引用
- Oliver A, Rojo-Molinero E, Arca-Suarez J, et al. Pseudomonasaeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group. Clin Microbiol Infect. 2023. PMID: 38160753. doi:10.1016/j.cmi.2023.12.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。